Merck also sells an antibiotic called Zerbaxa (ceftolozane and tazobactam) for cUTI and cIAI, that it acquired along with Cubist Pharma almost six years ago in a $9.5 billion deal. A landmark ...

Antibiotics is an area of interest to Merck - it paid $9.5 billion for Cubist and its big-selling Cubicin (daptomycin), used to treat resistant bacteria.